Abeona Therapeutics’ Post

🇺🇸 From Cleveland, Ohio, to the nation, Happy 4th of July. At Abeona Therapeutics, we're advancing cutting-edge gene and cell therapy to help those living with recessive dystrophic epidermolysis bullosa. This Independence Day, we celebrate the innovation and determination that drive us toward a brighter future for all. #IndependenceDay #cellandgenetherapy #RareDiseases #Innovation #AbeonaTherapeutics #RDEB #WeFightEB #PatrioticScience

Understanding leads to compassion and support. That is why knowledge is power. Swipe to learn 5 things about people living with Epidermolysis Bullosa. #wefightEB #whenyouknowyouknow #raredisease #EBLife #Abeonatherapeutics #Cellandgenetherapy

When you live with Recessive Dystrophic Epidermolysis Bullosa (RDEB), hope and life, like skin, are fragile. Watch and see how one RDEB dad is helping his daughter live with strength and pride. Happy Father's Day from Abeona Therapeutics.   #UnbreakableBonds #FathersDay #EBWarrior #WeFightEB #FamilyStrength #RDEB #Raredisease #Abeonatherapeutics

This week, Abeona Therapeutics is proudly attending the American Academy of Dermatology (AAD) Annual Meeting and the 36th Annual Society for Pediatric Dermatology Pre-AAD Meeting in San Diego. We are excited to be here and committed to supporting advancements in treatments for people living with severe dystrophic epidermolysis bullosa (DEB). Stay up to date on the latest advances in severe DEB by visiting bit.ly/3IpLygx #PreAAD2024 #AAD2024 #SevereDEB #RDEB #AbeonaTherapeutics #WeFightEB

This Rare Disease Day, listen to Dr. Karen Wiss talk about the possibilities and changing landscape of treatment for severe dystrophic epidermolysis bullosa (DEB) as we all work together to make a difference. At Abeona, we are dedicated to advancing therapies for severe DEB. Our commitment to innovation is steadfast, and every story of patient courage fuels our pursuit of new advancements. #WeFightEB #EpidermolysisBullosa #RDEB #SevereDEB #RareDiseaseDay

This morning, we provided an update on our progress on the FDA review for the pz-cel (prademagene zamikeracel) BLA for recessive dystrophic epidermolysis bullosa #RDEB, including completion by the FDA of both a Bioresearch Monitoring (BIMO) inspection of Abeona and the BLA mid-cycle review meeting. We are on track for the PDUFA date of May 25, 2024. Read our press release here bit.ly/3vZNGsm

Recessive Dystrophic Epidermolysis Bullosa is a rare genetic skin disorder. Children are born without collagen VII. That particular protein helps skin stay on the body. Without it, skin is fragile, it blisters and causes extreme pain every day. To learn more about the journey of those living with RDEB, click here bit.ly/46G4uky Abeona’s BLA submission for pz-cel for RDEB, has been accepted by the FDA for formal review with a PDUFA target action date of May 25, 2024. Read the press release here bit.ly/47SH5NZ #RDEB #raredisease #EBLife #Abeonatherapeutics

We are excited to enter into a $50 million credit facility with Avenue Venture Opportunities Fund, L.P. Proceeds from the facility are intended to support our ongoing preparations for launch and commercialization in anticipation of a potential FDA approval of pz-cel (prademagene zamikeracel) for recessive dystrophic epidermolysis bullosa #RDEB. Read our press release here: bit.ly/47p4R3r.

Season's Greetings and warm wishes for the New Year from Abeona Therapeutics! We're deeply thankful for the incredible support and collaboration within the epidermolysis bullosa community this year. Click here bit.ly/46G4uky to discover more about RDEB, often referred to as the worst disease you've never heard of. Abeona's BLA submission for pz-cel has been accepted by the FDA, marking a milestone with a PDUFA target action date of May 25, 2024. Read our press release for further details bit.ly/47SH5NZ #RDEB #raredisease #EBLife #Abeonatherapeutics #FightEB #EBawareness #NewYear #HappyNewYear #SeasonsGreetings